SUMMER 2022, THE EVIDENCE FORUM, WHITE PAPER
Summary
Chronic Kidney Disease (CKD) is a condition characterized by abnormalities of kidney structure or function, present for greater than three months. CKD is quite common in adults, with a significant rise in incidence of close to 30 percent over the last 30+ years. While appearance in children is extremely rare, those with CKD face many challenges, such as negative self-image, behavior and learning problems, delayed language and motor skills development and delayed growth rate compared to their healthy peers.
In this paper, we discuss:
- An assessment of metadata from Clinicaltrials.gov and publications from Pubmed.gov to characterize clinical research trends in CKD over the last 20 years
- Our approach in comparing two 10-year time periods (2002 to 2011 and 2012 to 2021) in terms of numbers of studies, study phases, study populations, type of interventions, endpoints
- Possibilities for future trajectories for treatment
Authors
Andrew Bevan, MRes, CSci, CBiol, MRSB, Executive Director Project Management, Peri- and Post-approval Interventional Studies
Evidera, a business of PPD, part of Thermo Fisher Scientific
Davide Garrisi, MSc, MBA, Executive Director Project Management, General Medicine
PPD, part of Thermo Fisher Scientific
Carmichael Angeles, MD, Senior Medical Director, Pharmacovigilance, Medical and Scientific Services
PPD, part of Thermo Fisher Scientific
Download the Advancing Treatments for Chronic Kidney Disease and Rare Renal Disorders White Paper
Fill out the form below to download this whitepaper.
